

IN THE CLAIMS

Please cancel claims 16, 19, 21, 23, 27, 28 and 30 without prejudice, and amend claims 17, 20 and 29, as follows:

1-16. (Canceled)

17. (Currently Amended) A humanized antibody specific for HBV surface antigen pre-S1, containing a humanized heavy chain variable region which comprises an amino acid sequence ~~described by~~ of SEQ ID NO: 21.

18. (Previously Presented) The humanized antibody of claim 17, wherein the amino acid sequence of the humanized heavy chain variable region is modified from SEQ ID NO: 21 by at least one amino acid substitution selected from the group comprising:

Lys <sup>12</sup> → Val <sup>12</sup> ,	Thr <sup>28</sup> → Ala <sup>28</sup> ,	Thr <sup>30</sup> → Ser <sup>30</sup> ,
Met <sup>48</sup> → Ile <sup>48</sup> ,	Arg <sup>67</sup> → Lys <sup>67</sup> ,	Val <sup>68</sup> → Ala <sup>68</sup> ,
Met <sup>70</sup> → Leu <sup>70</sup> ,	Val <sup>79</sup> → Ala <sup>79</sup> ,	and Tyr <sup>95</sup> → Phe <sup>95</sup> .

19. (Canceled)

20. (Currently Amended) A gene encoding a humanized heavy chain which comprises a humanized heavy chain variable region having an amino acid sequence selected from the group consisting of: ~~the amino acid sequence described by SEQ ID NO: 20;~~ the amino acid sequence

described by SEQ ID NO: 21; and the amino acid sequence of SEQ ID NO: 21 which is modified by at least one amino acid substitution selected from the group comprising: Lys<sup>12</sup> → Val<sup>12</sup>, Thr<sup>28</sup> → Ala<sup>28</sup>, Thr<sup>30</sup> → Ser<sup>30</sup>, Met<sup>48</sup> → Ile<sup>48</sup>, Arg<sup>67</sup> → Lys<sup>67</sup>, Val<sup>68</sup> → Ala<sup>68</sup>, Met<sup>70</sup> → Leu<sup>70</sup>, Val<sup>79</sup> → Ala<sup>79</sup>, and Tyr<sup>95</sup> → Phe<sup>95</sup>.

21. (Canceled)

22. (Previously Presented) The gene of claim 20, wherein the humanized heavy chain variable region comprises an amino acid sequence described by SEQ ID NO: 21.

23. (Canceled)

24. (Previously Presented) An expression vector containing the gene of claim 20.

25. (Previously Presented) The expression vector of claim 24, which is designated pCMV-HKR127HC (Accession Number: KCTC 0531BP).

26. (Previously Presented) The expression vector of claim 24, which is designated pCMV-HKR127(II)HC (Accession Number: KCTC 0691BP).

27. (Canceled)

28. (Canceled)

29. (Currently Amended) A ~~pharmaceutical~~ composition containing a humanized antibody specific for HBV surface antigen pre-S1, wherein the humanized antibody comprises:

- ~~(a) a humanized heavy chain variable region which comprises an amino acid sequence described by SEQ ID NO: 20;~~
- ~~(b)~~ (a) a humanized heavy chain variable region which comprises an amino acid sequence described by SEQ ID NO: 21; or
- (c) (b) a humanized heavy chain variable region which comprises an amino acid sequence of SEQ ID NO: 21 which is modified by at least one amino acid substitution selected from the group comprising: Lys<sup>12</sup> → Val<sup>12</sup>, Thr<sup>28</sup> → Ala<sup>28</sup>, Thr<sup>30</sup> → Ser<sup>30</sup>, Met<sup>48</sup> → Ile<sup>48</sup>, Arg<sup>67</sup> → Lys<sup>67</sup>, Val<sup>68</sup> → Ala<sup>68</sup>, Met<sup>70</sup> → Leu<sup>70</sup>, Val<sup>79</sup> → Ala<sup>79</sup>, and Tyr<sup>95</sup> → Phe<sup>95</sup>; or
- ~~(b) a humanized light chain variable region comprising an amino acid sequence described by SEQ ID NO: 23~~

30. (Canceled)